Prijeđi na sadržaj

Klonidin

Izvor: Wikipedija
Klonidin
(IUPAC) ime
N-(2,6-dihlorofenil)-4,5-dihidro-1H-imidazol-2-amin
Klinički podaci
Robne marke Catapres
AHFS/Drugs.com Monografija
MedlinePlus a682243
Identifikatori
CAS broj 4205-90-7
ATC kod C02AC01 N02CX02, S01EA04
PubChem[1][2] 2803
DrugBank DB00575
ChemSpider[3] 2701
UNII MN3L5RMN02 DaY
KEGG[4] D00281 DaY
ChEBI CHEBI:3757 DaY
ChEMBL[5] CHEMBL134 DaY
Hemijski podaci
Formula C9H9Cl2N3 
Mol. masa 230,093 g/mol
SMILES eMolekuli & PubHem
Farmakokinetički podaci
Bioraspoloživost 75-95%
Vezivanje za proteine plazme 20-40%
Metabolizam Hepatički do inaktivnih metabolita
Poluvreme eliminacije 12-33 sati
Izlučivanje urin (40-50%)
Farmakoinformacioni podaci
Trudnoća C(US)
Pravni status Prescription only
Način primene oralno, transdermalno

Klonidin je simpatolitički lek koji se koristi za tretiranje visokog krvnog pritiska, nekih oblika bola, ADHD i anksioznog/paničnog poremećaja. On je klasifikovan kao centralno delujući α2 adrenergički agonist.[6][7]

Sinteza

[uredi | uredi kod]

Klonidin, 2-(2,6-dihlorofenilamin)imidazolin, se može sintetisati iz 2,6-dihloroanilina, reakcijom u kojom sa amonijum tiocijanatom daje N-(2,6- dihlorofenil)tioureju. Metilacija ovog produkta, i naknadna reakcija sa etilen diaminom daje klonidin.[8][9][10][11][12][13][14]

Reference

[uredi | uredi kod]
  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.  edit
  4. Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H. 
  5. Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.  edit
  6. Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7. 
  7. Pdr Staff (2009). PDR: Physicians Desk Reference 2010 (Physicians' Desk Reference (Pdr)). Rozelle, N.S.W: Thomson Reuters. ISBN 1-56363-748-0. 
  8. K. Zeile, H. Staehle, K. H. Hauotman, DE 1303141  (1961).
  9. H. Stahle, K. Zeile, U.S. Patent 3.202.660 (1965).
  10. K. Zeile, K. H. Hauotman, H. Stahle, U.S. Patent 3.236.857 (1966).
  11. Boehringer Sohn Ingelheim, BE 653933  (1964).
  12. Boehringer Sohn Ingelheim, GB 1016514  (1962).
  13. Boehringer Ingelheim GmbH, GB 1034938  (1964).
  14. US patent 3937717, Šablon:Cite patent/authors, "2-Phenylamino-imidazolines-(2)", issued 10. 2. 1976., assigned to Boehringer Ingelheim GmbH 

Vanjske veze

[uredi | uredi kod]
pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy